Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amiselimod Long-term Extension in Crohn's Disease
NCT02389790Phase 2Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Aug 2015
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 2 trial of amiselimod in Crohn's disease, sponsored by Mitsubishi Tanabe Pharma Corporation. Started Aug 2015; status: completed.
02
Drugs
amiselimod
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02389790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02389790.